Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

HDAC2 maintains receptor tyrosine kinase signaling of undifferentiated pancreatic cancer cells

ABSTRACT: HDAC2 maintains receptor tyrosine kinase signaling of undifferentiated pancreatic cancer cells

PROVIDER: PRJNA655480 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR12395616.fastq.gz	Fastqsanger.gz
	SRR12395617.fastq.gz	Fastqsanger.gz
	SRR12395629.fastq.gz	Fastqsanger.gz
	SRR12395630.fastq.gz	Fastqsanger.gz

Items per page:

1 - 4 of 4

Similar Datasets

HDAC2 maintains receptor tyrosine kinase signaling of undifferentiated pancreatic cancer cells (ATAC-Seq)

Project description:HDAC2 maintains receptor tyrosine kinase signaling of undifferentiated pancreatic cancer cells (ATAC-Seq)

| PRJNA655483 | ENA

HDAC2 maintains receptor tyrosine kinase signaling of undifferentiated pancreatic cancer cells (ChIP-Seq)

Project description:HDAC2 maintains receptor tyrosine kinase signaling of undifferentiated pancreatic cancer cells (ChIP-Seq)

| PRJNA655482 | ENA

HDAC2 maintains receptor tyrosine kinase signaling of undifferentiated pancreatic cancer cells (ChIP-Seq)

Project description:H3K27ac ChIP-se and ATAC-seq were used to determine epigenetic differences between Hdac2 knockout versus Hdac2 wildtype pancreatic cancer cells.

2021-11-12 | GSE155752 | GEO

HDAC2 maintains receptor tyrosine kinase signaling of undifferentiated pancreatic cancer cells (ATAC-Seq)

Project description:H3K27ac ChIP-se and ATAC-seq were used to determine epigenetic differences between Hdac2 knockout versus Hdac2 wildtype pancreatic cancer cells.

2021-11-12 | GSE155751 | GEO

Tyrosine Kinase Inhibitor Cardiotoxicity

Project description:Tyrosine Kinase Inhibitor Cardiotoxicity

| PRJNA352077 | ENA

HDAC2 maintains receptor tyrosine kinase signaling of undifferentiated pancreatic cancer cells

Project description:This SuperSeries is composed of the SubSeries listed below.

2021-11-12 | GSE155753 | GEO

Fms-like tyrosine kinase 3 (Flt3) contributes to a receptor tyrosine kinase signature regulating the cardiac side population

Project description:Fms-like tyrosine kinase 3 (Flt3) contributes to a receptor tyrosine kinase signature regulating the cardiac side population

| PRJNA706448 | ENA

Fms-like tyrosine kinase 3 (Flt3) contributes to a receptor tyrosine kinase signature regulating the cardiac side population

Project description:Fms-like tyrosine kinase 3 (Flt3) is a regulator of hematopoietic progenitor cells. It is a target of tyrosine kinase inhibitors (TKIs) used for acute myeloid leukemia treatment. Flt3 and its ligand (Flt3L) are expressed in the heart and cardiac side effects occur under Flt3-targeting TKIs. Whether Flt3/Flt3L also regulate cardiac progenitor cells (CPCs), however, is not known. The cardiac side population (SP) is a pool of heterogenous CPCs that can give rise to all cardiac lineages, hence contributing to cardiovascular homeostasis. Here we show that SP-CPCs produce and are responsive to Flt3L. Compared to wild-type, SP-CPCs from flt3L-/- mice are less abundant, with less contribution of CD45-CD34+ cells, and lower expression of gene sets related to epithelial-to-mesenchymal transition, cardiovascular development and stem cell differentiation. Upon culturing and compared to wild-type, flt3L-/- Sca1+CD31- SP-CPCs show increased proliferation and less vasculogenic commitment, but differentiation can be induced in the presence of receptor tyrosine kinase-activating growth factors. The observed differences are associated with decreased microvascularisation and global systolic function of flt3L-/- hearts. Thus, Flt3 contributes to a receptor tyrosine kinase signature necessary for the maintenance and functionality of SP-CPCs. These findings have potential implications regarding cardiovascular side effects observed under TKI therapy.

2021-11-30 | GSE168207 | GEO

Histologic transformation induced by EGFR tyrosine kinase inhibitors

Project description:Histologic transformation induced by EGFR tyrosine kinase inhibitors

| PRJNA1145888 | ENA

Yes tyrosine kinase signaling promotes liver cancer development

Project description:Yes tyrosine kinase signaling promotes liver cancer development

| PRJNA744904 | ENA